Roztroušená skleróza: Helena jí trpí 20 let, přesto žije spokojený život | Blesk.cz
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
Polska Platforma Medyczna Polish Platform of Medical Research https://ppm.edu.pl Repozytorium Śląskiego Uniwersytetu Medyczneg
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations_ Integrated Analysis of the Delayed
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Clinical Advances in MS: Changing the Future for Patients
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges - Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová, Ludwig Kappos, Xavier Montalban, Carlo Pozzilli,
PDF) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Eva K. Havrdová: Nové trendy v léčbě RS | RS kompas
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate_ Experiences of an international
Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data - touchNEUROLOGY
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study | PLOS ONE
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield proces
Solen: On-line kurz pro praktické neurology 2/2022 - Léčba pacienta s RS v průběhu dekád života
Management of multiple sclerosis patients in central European countries: current needs and potential solutions
Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
Untitled
Nové informace ke Covid 19 a RS - prof. Havrdová | RS kompas
